In less than three weeks, American medicine produced two milestones worth noticing.

On Aug. 5, the Food and Drug Administration approved MFLUSIVA, Moderna’s influenza vaccine for adults 50 and older — the first flu vaccine in the United States built with messenger RNA, or mRNA.